Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017-present).
| Autor: | Zhang B; Jiangmen Central Hospital, Jiangmen, China., Jiang MY; State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, P. R. China., Luo WH; School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan, China., Zhang C; School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan, China., Wu Y; State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, P. R. China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2024 Nov; Vol. 34 (11), pp. 1105-1119. Date of Electronic Publication: 2024 Oct 09. |
| DOI: | 10.1080/13543776.2024.2412577 |
| Abstrakt: | Introduction: PDE2 is a dual-specific enzyme that hydrolyzes two intracellular substrates, cAMP and cGMP. PDE2 is mainly distributed in the brain, which indicates that PDE2 can serve as a potential target for central nervous system diseases without causing other peripheral side effects. Discovery of new mechanisms of PDE2 inhibitors is expected to bring new opportunities for the treatment of central nervous system diseases. Area Covered: This review aims to provide an overview of PDE2 inhibitors reported in patents from 2017 to present. Expert Opinion: In recent years, the development of PDE2 inhibitors and their application in the treatment of brain diseases have received much attention. The main reason is the high expression of PDE2 in the brain, which gives PDE2 a natural advantage as a research target for central nervous system diseases. This review summarizes the scaffolds of PDE2 inhibitors reported in various patents since 2017, as well as the scientific issues that need to be addressed in terms of subtype selectivity and metabolic stability, intending to provide insights for the discovery of highly active and selective PDE2 inhibitors in the future. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|